Presented at the 31st Annual Society for Maternal Fetal Medicine, San Francisco, CA, February 10, 2011.
Efficiency of first-trimester growth restriction and low pregnancy-associated plasma protein-A in predicting small for gestational age at delivery†
Article first published online: 2 MAY 2012
© 2012 John Wiley & Sons, Ltd.
Volume 32, Issue 8, pages 724–729, August 2012
How to Cite
Carbone, J. F., Tuuli, M. G., Bradshaw, R., Liebsch, J. and Odibo, A. O. (2012), Efficiency of first-trimester growth restriction and low pregnancy-associated plasma protein-A in predicting small for gestational age at delivery. Prenat. Diagn., 32: 724–729. doi: 10.1002/pd.3891
Funding sources: None
Conflicts of interest: None declared
- Issue published online: 26 JUL 2012
- Article first published online: 2 MAY 2012
To evaluate the efficiency of first-trimester fetal growth restriction (FGR), low pregnancy-associated plasma protein A (PAPP-A), and their combination for predicting small for gestational age (SGA) at delivery.
Retrospective cohort study of women undergoing first-trimester aneuploidy screening. Fetal crown–rump lengths (CRLs) were at 10 to 14 weeks’ gestation and converted to gestational age adjusted Z-scores. Low PAPP-A was defined as levels < 5th percentile for GA. Receiver-operating characteristic curves were used to assess screening efficiencies.
Among 3269 pregnancies meeting the inclusion criteria 185 (5.7%) infants were SGA. CRL Z-score < −1.0 standard deviation was identified as the optimal definition of early FGR. Using either CRL Z-score < −1.0 standard deviation or PAPP-A < 5th percentile had the highest sensitivity (33%) with a specificity of 82.1% when screening for SGA. Using a combination resulted in an increased association (adjusted odds ratio 4.23[confidence interval 1.37–13.03]) at the expense of significantly reduced sensitivity (3.13%).
First-trimester FGR and PAPP-A < 5th percentile are associated with delivery of an SGA infant. Neither of these parameters or the combination of the two are sufficient powerful predictors of SGA to be clinically useful screening tools. © 2012 John Wiley & Sons, Ltd.